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The abdominal aortic counterpulsation device is a round 
pumping chamber with a valveless opening which is im•
planted retroperitoneally on the abdominal aorta. The 
Utah driver is connected to the device through an air 
conduit and is synchronized on the electrocardiographic 
signal to provide diastolic aortic augmentation. For com•
parison an intraaortic balloon was also driven by the 
Utah driver system. The abdominal aortic counterpul•
sation device (stroke volume = 30, 40 and 60 ml) and 
the intraaortic balloon pump (balloon volume = 20 mt) 
were tested in dogs with acute left ventricular failure. 
The abdominal aortic counterpulsation device was also 
tested in normal animals. 
In acute left ventricular failure the abdominal aortic 
counterpulsation device at a stroke volume of 30, 40 or 
60 ml decreased left ventricular end-diastolic pressure 
by an average of 28.56 (p < 0.001), 39.56 (p < 0.001) 
and 44.14% (p < 0.005). respectively; aortic end-dia•
stolic pressure by 24.11 (p < 0.001), 26.67 (p < 0.001) 
Use of a mechanical device for temporary or permanent 
circulatory support in left ventricular failure has been vig•
orously investigated over the last 25 years. After the ex•
perimental work by Moulopoulos et al. (1) in 1962 and the 
clinical application by Kantrowitz (2) in 1967, aortic balloon 
pumping has become progressively more popular and it now 
serves as a routine clinical tool for assisting the circulation 
of patients with acute cardiac failure. Unfortunately, 24 to 
84% of such patients become balloon dependent (3-5). For 
treatment of medically and surgically intractable heart fail•
ure, there are four possible therapeutic approaches: cardiac 
transplantation and implantation of an artificial heart, left 
ventricular assist device or counterpulsation device. The 
latter is not currently available for clinical application. 
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and 19.57% (p < 0.01); and aortic systolic pressure by 
18.56 (p < 0.002), 26.0 (p < 0.001) and 22.43% (p < 
0.005). It increased cardiac index by 27.58 (p < 0.02), 
35.59 (p < 0.005) and 43.42% (p < 0.001) and it pro•
vided peak aortic diastolic augmentation of 64.5 (p < 
0.001), 69.78 (p < 0.001) and 74.43% (p < 0.001), re•
spectively, above the control aortic end-diastolic pres•
sure. 
The abdominal aortic counterpulsation device re•
sulted in a salutary change in these variables of 1.14 to 
2.55, 1.57 to 3.59 and 1.37 to 3.47 times greater than 
that produced by the intraaortic balh)l)n pump for the 
three stroke volumes. The superiority of the abdominal 
aortic counterpulsation device to the intraaortic balloon 
pump and the simplicity of its implantation, replacement 
and removal make it a promising device for interim and 
primary management of intractable heart failure. 
(J Am Coil CardioI1986;7:1028-35) 
Our previous work on implantation and operation, bio•
compatibility and hemodynamic effects in acute left ven•
tricular failure of the abdominal aortic counterpulsation de•
vice has been described (6,7). The present study was 
undertaken 1) to evaluate the effectiveness of the abdominal 
aortic counterpulsation device on preload and afterload of 
the left ventricle in normal animals, and 2) to compare 
hemodynamic effects of various stroke volumes of this de•
vice with those of the intraaortic balloon pump in dogs with 
acute left ventricular failure. 
Methods 
Prosthesis. The abdominal aortic counterpulsation de•
vice (Fig. 1) is a round pumping chamber that has a 100 
ml stroke volume when fully inflated. It was made using 
the same technique and materiais used for the Utah artificial 
heart (8). It has a single valveless orifice, 20 mm in di•
ameter, connected by a quick-connector (9) to a Dacron 
graft 20 mm in diameter and 1.5 to 3 em in length at a 30 
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Figure 1. The abdominal aortic counterpulsation device consists 
of an elastomeric segmented polyurethane housing. It has a single 
valveless orifice and a 100 ml maximal stroke volume. The diagram 
shows the position of the aortic counterpulsation device implanted 
on the abdominal aorta in a 30 to 45° angle with the distal ab•
dominal aorta. EeG = electrocardiogram. 
to 45° angle with the peripheral abdominal aorta. A gas 
conduit leads from the pumping chamber to the driver sys•
tem. The electrocardiogram is obtained with surface elec•
trodes. The Utah driver system is connected to the air con•
duit and provides a driving pressure of 220 to 250 mm Hg. 
The control unit is adjusted on the basis of the electrocar•
diogram signal to provide aortic diastolic augmentation, and 
the systolic time interval is adjusted to produce a stroke 
volume of 25 to 65 ml, as measured by the cardiac output 
monitor and diagnostic unit for pneumatically driven arti•
ficial hearts (10,11). 
An intraaortic balloon of 20 ml volume, the largest bal•
loon accommodated by the dog's aorta, was also driven by 
the Utah driver system with 7 to 8 psi driving pressure and 
14 to 16 inches (36 to 41 cm) vacuum pressure. 
Experimental procedure. Six short-term experiments 
were performed in normal sheep weighing 52 to 100 kg, 
and five in dogs weighing 29 to 37 kg. The animals were 
anesthetized with intravenous sodium phenobarbital (30 mglkg 
body weight). After intubation with a cuffed endotracheal 
tube, they were connected to a Bird mark 14 respirator and 
sodium phenobarbital was administered as needed to main•
tain anesthesia. Aortic pressure was monitored using an 8F 
Coumand catheter introduced into the right carotid artery 
and advanced into the aortic arch. The retroperitoneal cavity 
was entered through a left lateral oblique incision. The ab•
dominal aorta was half-clamped with a Satinski clamp. The 
Dacron graft was implanted with a double row of continuous 
sutures after an incision of the lateral abdominal aortic wall 
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distal to the origin of the renal arteries. The graft and the 
peripheral part of the abdominal aorta were connected at a 
30 to 45° angle (Fig. 1). The abdominal aorta was then 
unclamped, and the graft was clamped. With the graft 
clamped, we waited for several minutes to be certain he•
mostasis was satisfactory. 
The abdominal aortic counterpulsation device was then 
connected with a quick-connector to the Dacron graft, and 
the air within the device was evacuated with a needle. The 
gas conduit was connected to the Utah driver system. The 
electrocardiographic monitoring electrodes were placed at 
either side of the chest. The control unit was then adjusted 
on the basis of the electrocardiogram signal to provide aortic 
diastolic augmentation. Subsequently, the heart was ex•
posed through a left thoracotomy in sheep and a midster•
notomy in dogs and suspended in a pericardial cradle. A 
7F Coumand catheter was advanced through the right ven•
tricular outflow tract into the pulmonary artery. An 8F con•
ventional multipurpose catheter was placed into the left ven•
tricle by way of the apex. 
Measurements. After completion of the preparation, lost 
fluids were replaced, and at least 10 minutes was allowed 
for stabilization of all variables. In the six sheep, left ven•
tricular pressure, aortic pressures and cardiac output were 
obtained before and after 15 minutes of support with the 
abdominal aortic counterpUlsation device. This intervention 
was followed by another period of control measurements, 
another 15 minutes of assistance with the abdominal aortic 
counterpulsation device and a final control period. Control 
data were obtained in the five dogs; thereafter, left ventric•
ular failure was induced by ligation of the left anterior de•
scending coronary artery immediately beyond the origin of 
the first diagonal branch, followed by administration of pro•
pranolol, 1 mg/kg body weight every 15 to 20 minutes for 
a total dose of 4 to 8 mg/kg body weight, and blood trans•
fusions obtained from a donor dog. If the above measures 
did not induce sufficient heart failure, defined as left ven•
tricular end-diastolic pressure greater than 20 mm Hg and 
reduction of the cardiac output, the posterior descending 
coronary artery or the obtuse marginal arteries, or both, 
were ligated. To prevent ventricular arrhythmias, lidocaine 
was given at a rate of 2 mg/min after a 50 mg bolus. When 
adequate left ventricular failure was obtained, at least 15 
minutes was again allowed for stabilization of all variables. 
Then hemodynamic data were obtained immediately before 
and during 15 minutes of support with the intraaortic balloon 
pump or the abdominal aortic counterpulsation device. This 
intervention was followed by another period of control mea•
surements, a second 15 minute intervention with the alter•
nate device and a final control period. 
The abdominal aortic counterpulsation device was tested 
with different stroke volumes in each experiment, obtained 
by increasing the systolic period of the device. Thus, mean 
stroke volumes of 30, 40 and 60 ml of the device were 
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Table 1. Hemodynamic Effects of the Abdominal Aortic Counterpulsation Device on Nonnally Functioning Hearts 
CI 
LVEDP (mm Hg) AOEDP (mm Hg) AOSP (mm Hg) EVR PADA (mm Hg) (ml'mm-'.kg-'BW) 
AACD off 5.83 ± 0.94 83.17 ± 9.41 103.17 ± 13.14 1.23 ± 0.16 83.17 ± 9.41 78.5 ± 6.35 
AACD on 4.27 ± 0.65 71.83 ± 7.88 87.83 ± 19.94 2.03 ± 0.90 121.0 ± 23.2 79.08 ± 7.86 
AACD on- -1.57 ± 0.39 -11.33 ± 7.09 - 15.33 ± 11.6 0.80 ± 0.74 37.83 ± 16.3 0.58 ± 2.8 
AACD off 
Percent change - 26.67 ± 3.93 -13.33 ± 7.87 - 15.5 ± 11.54 59.2 ± 50.67 44.83 ± 18.21 0.67 ± 3.56 
from control 
p Value <0.001 <0.02 <0.05 NS <0.005 NS 
Values are means:±: SD. AACD = abdominal aortic counterpulsatIOn device; AOEDP = aortic end-diastolic pressure; AOSP = aortic systolic 
pressure; BW = body weight; CI = cardiac index; EVR = endocardial viability ratio; L VEDP = left ventricular end-diastolic pressure; PADA = peak 
aortic diastolIc augmentatiol1. 
tested. The intraflortic balloon pump was tested one or two 
times in each experiment and the abdominal aortic coun•
terpulsation device, with one to three different stroke vol•
umes, for a total of one to eight times in each experiment. 
While the intraaortic balloon pump was tested, the abdom•
inal aortic counterpulsation devlce was clamped in complete 
inflation. While the abdominal aortic counterpulsation de•
vice was testeq, the intraaortic balloon was pulled out through 
the right femoral artery, through which it had been placed. 
Aortic pressure, left ventricular end-diastolic pressure, car•
diac output by the dye-dilution method and the stroke vol•
ume of the abdominal aortic counterpUlsation device by the 
cardiac output monitor and diagnostic unit curves were re•
corded. 
Statistical analysis. Student's t test was useq for paired 
observations and the t test for independent means was used 
to compare the percent change of each variable induced by 
each device. Values are reported as mean ± SD. 
Results 
These devices affected six measured or calculated vari•
ables: 1) left ventricular end-diastolic pressure, 2) aortic 
end-diastolic pressure, 3) aortic systolic pressure, 4) en•
docardial viability ratio, which represents the ratio of dia•
stolic pressure-time index to tension-time index and is con•
sidered analogous to the ratio of oxygen availability/oxygen 
consumption of the myocardium (12), 5) peak aortic dia•
stolic augmentation, and 6) cardiac index. 
Hemodynamic effects of the abdominal aortic coun•
terpulsation device on normally functioning left ventri•
cle. In the normally functioning left ventricle (Table 1) the 
abdominal aortic counterpulsation device decreased the left 
ventricular end-diastolic pressure by 26.67 ± 3.93% below 
control (p < 0,001), the aortic end-diastolic pressure by 
13.33 ± 7.87% (p < 0.02) and the aortic systolic pressure 
by 15.5 ± 11.54% (p < 0.05). It increased the endocardial 
viability ratio by 59.2 ± 50.67% above control (p == NS) 
and the peak aortic diastolic augmentation by 44.83 ± 
18.21 % (p < 0.005). The cardiac index remained almost 
unchanged. 
Left ventricular failure. Left ventricular failure was 
characterized by a left ventricular end-diastolic pressure of 
29.1 ± 7.4 mm Hg and a reduction of the cardiac index 
by 35.6 ± 26.9% (p < 0.001). 
Hemodynamic effects of the abdominal aortic coun•
terpulsation device on left ventricular failure using dif•
ferent stroke volumes. Increased abdominal aortic coun•
terpulsation device stroke volume had a generally greater 
beneficial effect on all the measured variables (Tables 2, 3 
and 4, Fig. 2 and 3). The left ventricular end-diastolic pres•
sure decreased by a mean of 28.56 (p < 0.001), 39.56 (p 
< 0.001) and 44.14% (p < 0.005) below control value with 
stroke volumes of 30, 40 and 60 mI. respectively. The aortic 
Table 2. Hemodynamic Effects of the Abdominal Aortic Counterpulsation Device on Acute Left Ventricular Failure 
(stroke volume == 30 ml) 
L VEDP (mm Hg) AOEDP (mm fig) AOSP (mm Hg) EVR PADA (mm Hg) CI (ml.mm-'.kg-' BW) 
AACD off 30.56 ± 8.63 79.22 :±: 12.8 100.11 ± 13.51 0.95 ± 0.44 79.22 ± 12.8 41.92 ± 11.85 
AACD on 21.78 :±: 7.55 60.11 :±: 10.94 81.78 :±: 18.03 1.71 :±: 0.50 130.75 :±: 23.86 51.4 ± 6.97 
AACD on- -8.78 :±: 3.93 -19.11 :±: 8.85 -18.33 ± 11.87 0.75 :±: 0.34 50.63 ± 16.81 9.48 ± 6.25 
AACD off 
Percent change - 28.56 ± 22.59 - 24.11 :±: 9.43 -18.56 :±: 11.I4 101.11 :±: 69.28 64.5 ± 20.91 27.58 ± 23.28 
from control 
p Value <0.001 <0.001 <0.002 <0.002 <0.001 <0.02 
Values are means ± SD. AbbreviatIOns as in Table I. 
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Table 3. HemodynamIc Effects of the Abdommal Aortic Counterpulsation Device on Acute Left Ventricular Failure 
(stroke volume = 40 ml) 
L VEDP (mm Hg) AOEOP (mm Hg) AOSP (mm Hg) EVR PAD A (mm Hg) CI (ml.min - I.kg - I BW) 
AACO off 25.67 :±: 7 16 90.0 :±: 9.15 114.56 :±: 9.37 1.13 :±: 0.34 900 :±: 9.15 52.23 :±: 20.52 
AACD on 15.56 :±: 4.88 66.0 :±: 12.37 84.67 :±: 13.43 2.11 :±: 0.38 151.67 ± 18.02 69.54 ± 27.21 
AACD on- - 10.11 ± 2.85 - 24.0 ± 10.52 - 29.89 :±: 13.83 0.99 :±: 0.40 61 67 ± 192 17 31 :±: 9.58 
AACD off 
Percent change -39.56 ± 5.7 - 26.67 ± 11.32 - 26.0 ± 11.07 100 78 ± 60.12 69.78 ± 26.09 35.59 ± 15.27 
from control 
p Value <0.001 <0.001 <0.001 
Values are means ± SO. Abbreviations as in Table I. 
end-diastolic pressure decreased by a mean of 24.11 (p < 
0.001),26.67 (p < 0.00l) and 19.57% (p < 0.01) and the 
aortic systolic pressure by a mean of 18.56 (p < 0.002), 
26.0 (p < 0.001) and 22.43% (p < 0.005) with the three 
stroke volumes. The endocardial viability ratio increased by 
a mean of lOLl I (p < 0.001), 100.78 (p < 0.001) and 
106.43% (p < 0.00l), respectively. The peak aortic dia•
stolic augmentation increased by a mean of 64.5 (p < 0.00 I), 
69.78 (p < 0.001) and 74.43% (p < 0.001) and the cardiac 
index increased by a mean of 27.58 (p < 0.02), 35.59 (p 
< 0.005) and 43.42% (p < 0.001). All of these individual 
variables except endocardial viability ratio had a tendency 
to improve when the stroke volume was increased from 30 
to 40 ml. with a statistically significant improvement in left 
ventricular end-diastolic pressure (p < 0.05). The improve•
ment was less when stroke volume was increased from 40 
to 60 ml. In fact, aortic end-diastolic pressure and aortic 
systolic pressure fell less with stroke volume set at 60 than 
at 40 ml. 
Comparison of effects of the abdominal aortic coun•
terpulsation device with those of the intraaortic balloon 
pump (Table 5, Fig. 3 and 4). With a stroke volume of 
30 ml, the abdominal aortic counterpulsation device, as 
compared with the balloon pump, decreased the left ven•
tricular end-diastolic pressure I. 14 times as much (p = 
NS)' the aortic end-diastolic pressure 1.69 times as much 
(p < 0.02) and the aortic systolic pressure 2.55 times as 
much (p < 0.02); it increased the endocardial viability ratio 
1.86 times as much (p = NS), the peak aortic diastolic 
<0.001 <0.001 <0.005 
augmentation 1.98 times as much (p < 0.005) and the 
cardiac index 2.2 times as much (p = NS). 
With a stroke volume of 40 ml, the abdominal aortic 
counterpulsation device, as compared with the balloon pump, 
decreased the left ventricular end-diastolic pressure 1.57 
times as much (p < 0.05), the aortic end-diastolic pressure 
1.87 times as much (p < 0.02) and the aortic systolic pres•
sure 3.59 times as much (p < 0.001); it increased the eJl•
docardial viability ratio 1.86 times as much (0.05 < P < 
0.1), the peak aortic diastolic augmentation 2.15 times as 
much (p < 0.005) and the cardiac index 2.84 times as much 
(p < 0.01). 
With a stroke volume of 60 mi. the abdominal aortic 
counterpulsation device. again compared with the balloon 
pump, decreased the left ventricular end-diastolic pressure 
1.76 times as much (p < 0.05), the aortic end-diastolic 
pressure 1.37 times as much (p = NS) and the aortic systolic 
pressure 3.09 times as much (p < 0.005); it increased the 
endocardial viability ratio 1.96 times as much (0.05 < P < 
O. 1), the peak aortic diastolic augmentation 2.29 times as 
much (p < 0.001) and the cardiac index 3.47 times as much 
(p < 0.005). 
Discussion 
Counterpulsation technique using the two devices. It 
has been shown that the efficacy of the counterpulsation 
technique using the intraaortic balloon pump diminishes in 
severe heart failure (13). This limitation of the effectiveness 
Table 4. Hemodynamic Effects of the Abdominal Aortic Counterpulsation Device on Acute Left Ventricular Failure (stroke volume 
= 60 ml) 
LVEDP (mm Hg) AOEDP (mm Hg) AOSP (mm Hg) EVR PADA (mm Hg) CI (ml·mm-I.kg- I BW) 
AACD off 28.29 ± 7.7 94.43 :±: 11.57 116.43 :±: 11.49 I 33 ± 0.39 94.43 :±: 11.57 40.08 ± 12.61 
AACD on 15.29 :±: 5.25 75.43 ± 11.04 89.57 ± 11.4 2.55 ± 0.22 163.57 ± 15.4 56.06 :±: 12.09 
AACO on- -13.0 ± 7.72 -19.0 :±: 13.04 -26.86 ± 1513 1.22 ± 0.51 69.14 ± 11.23 15.98 ± 2.64 
AACO off 
Percent change -44 14 :±: 15.66 - 19 57 :±: 12.31 -22.43 ± 11.15 106.43 ± 63.25 74.43 :±: 16.47 43.42 :±: 16.24 
from control 
p Value <0.005 <0.01 <0.005 <0.001 <0.001 <0001 
Values are means:±: SO Abbreviations as in Table 1 
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Figure 2. Tracing obtained from a dog after induction 
of acute left ventricular failure. With the abdominal 
aortic counterpulsation device (AACD) on stroke vol•
umes (SV) of: a, 30 ml, b, 40 ml and c, 60 m!. The 
effectiveness of the device becomes greater with greater 
stroke volume. AOP = aortic pressure; DP = driving 
pressure; EeG = electrocardiogram; FAP = femoral 
artery pressure; L VP = left ventricular pressure. 
Figure 3. Hemodynamic effects of the intraaortic 
balloon pump (lABP) (balloon volume = 20 m\) and 
abqominal aortic counterpulsation device (AACD) 
(stroke volume (SV] = 30, 40 and 60 ml) in dogs 
after the induction of acute left ventricular failure. 
Nearly all the hemodynamic effects of the abdominal 
aortic counterpulsation device were greater than those 
of the intraaortic balloon pump. AOEDP = aortic 
end-diastolic pressure; AOSP = aortic systolic pres•
sure; CI = cardiac index; EVR = endocardial via•
bility ratio; L VEDP = left ventricular end-diastolic 
pressure; PADA = peak aortic diastolic augmenta•
tion. 
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Figure 4. Tracing obtained from a dog after induction of acute 
left ventricular failure, a, Without any intervention. b, With the 
intraaortic balloon pump (IABP) on balloon volume = 20 m!. c, 
With the abdominal aortic counterpulsation device (AACD) on 
stroke volume = 40 ml, The diastolic augmentation and the effects 
of the abdominal aortic counterpulsation device on preload and 
afterload of the left ventricular were greater than those of the 
intraaortic balloon pump, Abbreviations as in Figures 2 and 3, 
of the intraaortic balloon pump has both physiologic and 
physical causes, The most important physical variable is the 
size of the balloon, which has to have a diameter less than 
95% of the diameter of the descending aorta (14) to be safe 
and less destructive to blood cells, This results in a 40 ml 
maximal volume for clinical use, The most important phys•
iologic variable is probably the aortic pressure which, when 
it is markedly decreased (aortic systolic pressure < 70 mm 
Hg) (13), causes the intraaortic balloon pump to be inef•
fective. This is probably the result of an increase in aortic 
compliance (15), which requires a larger balloon volume 
for the intraaortic balloon pump to be effective, 
In contrast to the intraaortic balloon pump, the abdominal 
aortic counterpulsation device can operate with as much 
volume as needed, The stroke volume of this device is 
limited only by the diameter of the graft, which for safety 
reasons must have a diameter not greater than that of the 
diameter of the abdominal aorta at the site of implantation. 
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According to Poiseuille's equation, flow in rigid tubing is 
expressed as: 
(Pressure difference) x (radius)4 
Fluid flow = -.:...-------.:....-....:--~­
(Tube length) x (fluid viscosity) x 8 
Thus, the maximal stroke volume of the abdominal aortic 
counterpulsation device, for a given cardiac cycle length, 
is proportional to the pressure difference between the pres•
sure of the device and the aortic pressure during the systolic 
and diastolic phases of the device, and the fourth power of 
the graft radius, It is inversely proportional to graft length. 
In the present study the mean maximal stroke volume of 
the abdominal aortic counterpulsation device was 60 ml 
whereas balloon volume was 20 ml, which is the maximal 
applicable volume in animals of this size, 
Hemodynamic effects of the abdominal aortic coun•
terpulsation device and the intraaortic balloon pump. The 
hemodynamic effects of the abdominal aortic counterpul•
sation device on the normally functioning left ventricle were 
similar to those reported in our previous work (6,7) on left 
ventricular failure of moderate degree. The hemodynamic 
effects of the intraaortic balloon pump in our study were 
similar to those reported by other investigators (13,14,16). 
The effects of the abdominal aortic counterpulsation device 
on aortic end-diastolic pressure and the peak aortic diastolic 
augmentation in the failing left ventricle were similar to 
those reported in our previous work (6,7). The left ventric•
ular end-diastolic pressure and the cardiac index were im•
proved more in this study than in the previous studies, 
probably because more severe heart failure was induced in 
this study, The endocardial viability ratio was increased 
more in this study because of a greater decrease in left 
ventricular end-diastolic pressure, which in tum increased 
the diastolic pressure time index, 
Hemodynamic effects of the abdominal aortic coun•
terpulsation device with different stroke volumes. The 
abdominal aortic counterpulsation device was tested at three 
different stroke volumes (30, 40 and 60 ml) and showed a 
trend toward increasing salutary effect on almost all vari•
ables as the stroke volume was increased from 30 to 40 ml, 
This trend was not seen in all variables when the stroke 
volume increased from 40 to 60 m!. It is likely that the most 
Table 5. Hemodynamic Effects of the Intraaortic Balloon Pump (Balloon Volume 20 ml) on Acute Left Ventricular Failure 
L VEOP (mm Hg) AOEOP (mm Hg) AOSP (mm Hg) EVR PAOA (mm Hg) CI (ml.min-'.kg- ' BW) 
IABP off 31.13 ± 7.77 94,38 ± 20.55 117.75 ± 22.84 0.89 ± 0.40 94.38 ± 20.55 44,34 ± 22.69 
IABP on 23.25 ± 8.45 81.5 ± 1932 100.25 ± 21.98 1 3 ± 0.38 123,0 ± 18,3 48.36 ± 22.03 
IABP on- -7.88 ± 6.01 -12.88 ± 3.76 -85 ± 6.5 0.41 ± 0 16 28.63 ± 3.07 4.01 ± 2.43 
IABP off 
Percent change 025,13 ± 16.32 -14.25 ± 4.4 -7.25 ± 4.53 54.29 ± 26.31 32.5 ± 12.18 12,53 ± 11.97 
from contIOI 
p Value <0.01 <0,001 <0.01 <0.001 <0.001 <0005 
Values are means ± SO. IABP == intraaortic balloon pump; other abbreviations as in Table I. 
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important factor accounting for this plateau of effect is the 
technique that was used to increase the stroke volume of 
the device. The onset of augmentation was established at a 
fixed delay after the sensed QRS complex. Stroke volume 
was then increased by lengthening the systolic period of the 
device. Thus, the increase in stroke volume of the device 
was accompanied by an early decrease in the diastolic period 
of the device. This resulted in a decrease in the amount of 
blood displaced before the onset of aortic valve opening, 
which in tum created higher aortic end-diastolic pressure. 
The smaller decrease in the aortic end-diastolic pressure 
when the stroke volume was increased from 40 to 60 ml 
may explain the lack of further increase in the endocardial 
viability ratio. It is not clear why this ratio did not increase 
when the stroke volume was increased from 30 to 40 m!. 
Factors that may have contributed to the discrepancy be•
tween the endocardial viability ratio and the remaining 
hemodynamic variables are an increase in aortic compli•
ance, a decrease in cardiac cycle length, or both. 
Comparison of the hemodynamic effects of the ab•
dominal aortic counterpulsation device with those of the 
intraaortic balloon pump. The abdominal aortic counter•
pulsation device (stroke volume 40 and 60 m!) had an av•
erage beneficial effect on each individual hemodynamic 
variable from 1.37 to 3.59 times that of the intraaortic bal•
loon pump. This greater efficacy was mainly due to the 
larger stroke volume of the abdominal aortic counterpul•
sation device, resulting in a greater decrease in the afterIoad 
of the left ventricle (17-22). Other variables, such as the 
velocity of decrease in aortic volume during the presystolic 
and ejection periods of the left ventricle, the velocity of 
increase in aortic volume during the aortic diastolic aug•
mentation period and the absolute expansion by the abdom•
inal aortic counterpulsation device of the total aortic volume, 
probably contributed to the greater efficacy of the abdominal 
aortic counterpulsation device. 
Implantation procedure of the abdominal aortic coun•
terpulsation device. The practicality of the surgical pro•
cedure is evident from the short procedure time (about 1.5 
hours) and the absence of complications in our experiments. 
The most serious potential complications of this procedure 
are hemorrhage of the abdominal aorta and ischemic injury 
to the organs that originate from the abdominal aorta. These 
complications could be avoided by using a graft with a 
diameter equal to or smaller than that of the abdominal aorta 
at the site of implantation and by implanting the graft on 
the lateral wall of the abdominal aorta in an area where no 
artery ligation is needed. 
Conclusions. This study demonstrates the superiority of 
the abdominal aortic counterpulsation device over the in•
traaortic balloon pump in brief treatment of experimental 
congestive heart failure. It suggests the possibility that this 
device, because it is implantable, could be used for treatment 
not only of acute intractable heart failure but also of chronic 
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heart failure. Furthermore, its implantation is a simple op•
erative procedure, and it can be easily and rapidly replaced 
using the quick-connector. These characteristics of the ab•
dominal aortic counterpulsation device make it a suitable 
device for the management of balloon-dependent patients 
who require long-term mechanical support to become can•
didates for more definitive therapy (5,23-25), for patients 
who await cardiac transplantation and require mechanical 
assistance (26-28) and for patients with severe reversible 
myocardial dysfunction (for example, acute myocarditis). 
Experiments in a model of chronic congestive heart failure 
would be desirable. 
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